PMID- 31723206
OWN - NLM
STAT- MEDLINE
DCOM- 20201112
LR  - 20210110
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Nov 13
TI  - Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization 
      interpretation in invasive breast cancers with immunohistochemically equivocal 
      results.
PG  - 16726
LID - 10.1038/s41598-019-53003-w [doi]
LID - 16726
AB  - The American Society of Clinical Oncology (ASCO)/College of American Pathologists 
      (CAP) recently issued updated guidelines on human epidermal growth factor 
      receptor 2 (HER2) testing by fluorescence in situ hybridization (FISH) in 
      invasive breast cancers. In this study, we aimed to investigate the impact of the 
      new recommendations on HER2 FISH interpretation in invasive breast cancers with 
      immunohistochemically (IHC) equivocal results. 1810 breast cancer cases with IHC 
      equivocal results were enrolled in this study between January 2012 and May 2019. 
      Concomitant IHC was performed on the same tissue blocks detected by FISH testing. 
      According to the 2018 guidelines, all the cases in ISH group 2 were categorized 
      as HER2 negative; three of four cases in ISH group 3 were considered as HER2 
      positive, while the one scored IHC 1+ was reclassified as HER2 negative; 
      Fifty-three previously ISH equivocal cases were redistributed into ten 
      HER2-positive cases and forty-three HER2-negative cases. In conclusion, the 
      utility of 2018 ASCO/CAP guidelines resulted in a slight decrease in HER2 
      positive rate, due to the reclassification of cases in ISH group 2 and group 4. 
      The implementation of the new guidelines can reduce reflex FISH test and make the 
      diagnosis of HER2 gene status more definitive.
FAU - Wang, Bo
AU  - Wang B
AD  - Department of Pathology, the first affiliated hospital of Zhejiang University, 
      Qingchun Road 79#, Hangzhou, China.
FAU - Ding, Wei
AU  - Ding W
AD  - Department of Pathology, the first affiliated hospital of Zhejiang University, 
      Qingchun Road 79#, Hangzhou, China.
FAU - Sun, Ke
AU  - Sun K
AD  - Department of Pathology, the first affiliated hospital of Zhejiang University, 
      Qingchun Road 79#, Hangzhou, China.
FAU - Wang, Xiaoling
AU  - Wang X
AD  - Department of Pathology, the first affiliated hospital of Zhejiang University, 
      Qingchun Road 79#, Hangzhou, China.
FAU - Xu, Liming
AU  - Xu L
AD  - Department of Pathology, the first affiliated hospital of Zhejiang University, 
      Qingchun Road 79#, Hangzhou, China.
FAU - Teng, Xiaodong
AU  - Teng X
AD  - Department of Pathology, the first affiliated hospital of Zhejiang University, 
      Qingchun Road 79#, Hangzhou, China. teng1102069@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20191113
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/metabolism/*pathology
MH  - Carcinoma, Ductal, Breast/genetics/metabolism/*pathology
MH  - Carcinoma, Lobular/genetics/metabolism/*pathology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry/*standards
MH  - In Situ Hybridization, Fluorescence/*standards
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Practice Guidelines as Topic/*standards
MH  - Prognosis
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Retrospective Studies
MH  - Societies, Medical
PMC - PMC6854277
COIS- The authors declare no competing interests.
EDAT- 2019/11/15 06:00
MHDA- 2020/11/13 06:00
PMCR- 2019/11/13
CRDT- 2019/11/15 06:00
PHST- 2019/08/22 00:00 [received]
PHST- 2019/10/25 00:00 [accepted]
PHST- 2019/11/15 06:00 [entrez]
PHST- 2019/11/15 06:00 [pubmed]
PHST- 2020/11/13 06:00 [medline]
PHST- 2019/11/13 00:00 [pmc-release]
AID - 10.1038/s41598-019-53003-w [pii]
AID - 53003 [pii]
AID - 10.1038/s41598-019-53003-w [doi]
PST - epublish
SO  - Sci Rep. 2019 Nov 13;9(1):16726. doi: 10.1038/s41598-019-53003-w.